Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

[Clinical Evaluation of Immunosuppressive Acidic Protein in the Serum of Patients with Inflammatory Breast Recurrence].

Inflammatory breast recurrence after breast conserving surgery often compromises patient quality of life(QOL)and is associated with a poor prognosis. For this type of recurrence, the immunological situation of the patient is uncertain. We evaluated the clinical significance of immunosuppressive acidic protein(IAP)in the serum of patients with inflammatory breast recurrence during treatment. We collected serum from 3 patients at three different time points: the pre-treatment phase, recurrence phase, and the post-treatment phase. IAP was then measured from these multiple serum samples. There was a significant difference between serum IAP values in the pre-treatment and recurrence phases. The recurrence phase had a mean IAP value that was higher than the pre-treatment phase. The IAP values were indicative of the disease condition. These results suggest that serum IAP is a useful quantification of the immunological condition of patients with inflammatory breast recurrence.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app